Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 5 Mar 2020 |
| Orion Corporation: Managers’ transactions – Olli Huotari | 3 Mar 2020 |
| Orion Corporation: Managers’ transactions – Virve Laitinen | 3 Mar 2020 |
| Orion Corporation: Managers’ transactions – Liisa Hurme | 3 Mar 2020 |
| Orion Corporation: Managers’ transactions – Christer Nordstedt | 3 Mar 2020 |